On July 1, 2026, the DEA published a notice of intent to temporarily place SR-17018 in Schedule I - the same category as heroin. The DEA has not opened a public comment period - but your story still matters, and now is the time to write it down.
The best way to help is to answer the questions below. Sharing your story helps us make the most compelling case possible to the DEA that scheduling SR-17018 could lead to a public health crisis. Then, pick up the phone and call. We'll create a personalized call script for you that is concise, powerful, and includes all the important information the government wants to hear.
This is the most important moment in the history of this community. Thank you for being a part of it!
How long have you been using SR-17018 products?
How much SR-17018 do you take on a typical day?
Your total across the whole day. Not sure? Check your package.
What does your SR-17018 routine look like?
Some people take it every day, others run it in cycles with planned breaks.
Have you ever had a serious adverse event or problem from your typical SR-17018 serving?
This might include an overdose scare, a medical event, a trip to the ER, or more.
What is the primary reason you take SR-17018?
Does it help with anything else? (optional)
Select all that apply.
What did you take to manage your symptoms prior to SR-17018?
Select all that apply.
If you've dealt with withdrawal or cravings, rate them on a 1–10 scale: 1 = barely noticeable, 10 = it ran my life. Skip anything that doesn't apply to you.
Withdrawal severity BEFORE SR-17018 (optional)
Cravings severity BEFORE SR-17018 (optional)
Withdrawal severity WITH SR-17018 (optional)
Cravings severity WITH SR-17018 (optional)
How would you describe SR-17018's effects on you? (optional)
What it feels like, what it does and doesn't do for you, and how that compares to what you took before. Decision-makers have almost no first-hand accounts of this compound — yours may be the first they read.
Tell us your story.
This is the heart of your call. What was life like before SR-17018, and what's different now? The honest details are what make your story impossible to ignore; if SR-17018 changed or saved your life, this is the place to say it.
Do you support the current proposed rule?
The proposal: SR-17018 becomes Schedule I - the same category as heroin - effective on or after July 31, 2026.
What would you consider turning to if SR-17018 gets banned?
This is the risk the government is required to weigh - you can be honest. Select all that apply.
Is there anything you want the government to understand about that? (optional)
Required. Your email will not be shared with the government.
Finds your members of Congress. Staffers ask for it to check you're a constituent.
Are you a veteran?
The Rights and Reason Project is leading the legal battle against this scheduling action.
“The outreach, survey, and petitions are very useful, but they only matter if we can get our day in court, and that will take lawyers and, unfortunately, money.”
Soren, Rights and Reason Project
Every contact is counted. You do not need to be an expert and you do not need to talk long. Tap a number to dial, and open an office to see what to say.
HHS
U.S. Department of Health and Human Services
When they pick up
Hi, I'm calling with an urgent public health concern about the DEA's proposed emergency Schedule I placement of SR-17018. Can you direct me to the office that handles controlled substance scheduling and scientific evaluation?
Once you are connected
Hello, my name is [your name]. I'm calling about the DEA's proposed emergency Schedule I placement of SR-17018. I'm asking HHS to review the evidence specific to SR-17018, and to consider what Schedule I placement would mean for people who rely on it and for research into pain and opioid dependence. Please help make sure this is not shut down before anyone understands it.
DEA
Drug Enforcement Administration
Headquarters: 202-307-1000
When they pick up
Hi, I'm calling about the DEA's proposed emergency Schedule I placement of SR-17018. Could you transfer me to the Diversion Control Division, or whoever is handling the temporary scheduling action for SR-17018, so I can formally voice my concern?
Once you are connected
Hello, my name is [your name]. I'm calling about the proposed emergency Schedule I placement of SR-17018. I'm asking the DEA to remove SR-17018 from this emergency scheduling action and evaluate it on evidence specific to this compound. People with lived experience should have a chance to be heard before it is placed in Schedule I.
NIDA
National Institute on Drug Abuse
General inquiries: 301-443-6441
When they pick up
Hi, I'm concerned about the effect of the DEA's proposed emergency Schedule I placement of SR-17018. Given NIDA's mission, can you direct me to the right person or office to share that with?
Once you are connected
Hello, my name is [your name]. I want to share a concern with NIDA leadership about what emergency Schedule I placement of SR-17018 could mean for research into opioid dependence, withdrawal, tolerance and pain. At a time when we badly need better answers for opioid dependence and chronic pain, promising work should be investigated, not obstructed.
NIH
National Institutes of Health
Main: 301-496-4000
When they pick up
Hi, I'm concerned about the effect of the DEA's proposed emergency Schedule I placement of SR-17018 on scientific research. Can you direct me to the scientific leadership office where I can raise that?
Once you are connected
Hello, my name is [your name]. I'm calling to formally raise a concern about the DEA's proposed emergency Schedule I placement of SR-17018. SR-17018 came out of legitimate scientific research and has published preclinical findings involving opioid tolerance, withdrawal and pain. I'm asking NIH to support continued rigorous research into it and to examine how emergency Schedule I placement would affect scientists' ability to study it.
FDA
Food and Drug Administration
CDER: 855-543-3784
Alternate: 301-796-3400
When they pick up
Hi, I have a concern about the DEA's proposed emergency Schedule I placement of SR-17018. Can you direct me to the office responsible for controlled substance scientific evaluation or scheduling recommendations?
Once you are connected
Hello, my name is [your name] and I'm calling to formally submit a concern. I'm asking the FDA to make sure SR-17018 gets an evidence based scientific evaluation specific to this compound, and that its existing research and potential uses are fully considered. Please help make sure decisions about SR-17018 are based on its own evidence rather than grouping it with other compounds.
ONDCP
White House Office of National Drug Control Policy
How to send it
Mark your message as concerning ONDCP and federal drug policy.
What to say
I'm contacting the Office of National Drug Control Policy about the DEA's proposed emergency Schedule I placement of SR-17018, which could take effect on or after July 31, 2026. I'm concerned that emergency scheduling would cut off both access and research for a compound with published findings involving opioid withdrawal, tolerance and pain. I'm asking ONDCP to look at this action in light of our national response to addiction, overdose and chronic pain, and whether SR-17018 should be evaluated on its own evidence.
OSTP
White House Office of Science and Technology Policy
How to send it
Ask that your message be forwarded to staff responsible for biomedical research, public health or federal science policy.
What to say
I'm contacting OSTP with an urgent concern about the effect of the DEA's proposed emergency Schedule I placement of SR-17018 on scientific research. SR-17018 has a published body of preclinical research involving pain, opioid tolerance and withdrawal. I'm asking OSTP to examine the impact of emergency Schedule I placement on that research and to advocate for an evidence based approach. Scientists should be able to investigate both the benefits and the risks before we close the door.
Whenever you call or write, ask for:
Write down what you are told. Knowing which office and which person is handling this is how the next call gets further than the last one.
In addition to helping you write your call script, the information you share here is intended to be anonymized and shared with lawmakers to give a more informed view into how people actually use SR-17018. We never publish anything you enter, and we never call or submit anything on your behalf.
© 2026 TestMyKratom | Terms | Grading System